Genenta Science SPA【GNTA】株式ニュース | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Genenta Science SPA (GNTA)
Genenta Science SPA (GNTA) ニュース

Genenta Science SPA (GNTA)

3.97

-0.01

(-0.25%)

終了 3月30日 5:00AM

3.97

0.00

(0.00%)

取引時間後: 5:25AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES...

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in...

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Monksdream

Monksdream 3月前

Monksdream

Monksdream 3月前

Monksdream

Monksdream 5月前

Awl416

Monksdream

Monksdream 11月前

Luckypennyman

Luckypennyman 2年前

FDA’s decision to grant Orphan Drug Designation to Temferon

glta

makinezmoney

makinezmoney 2年前

$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up

GO $GNTA

conix

Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.

asser_al7ob

asser_al7ob 3年前

is this genta that we have before, it is coming back after years

Phosphene

Phosphene 3年前

Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001

Genenta Science

Digital Magics S.p.A

Investec Bnk 23

Republic of France Bond ...

The Schiehallion

Banca Monte Dei Paschi D...

Societe Generale Societe...

DJ Automobiles and Parts...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約